TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD
Share
Subscribe
Michael J. Mauro, MD, discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.
In today’s episode, we spoke with Michael J. Mauro, MD, an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.
In our exclusive interview, Dr Mauro discussed the vast assortment of TKIs available for the treatment of patients with chronic myeloid leukemia (CML). In addition to breaking down numerous different TKIs that he turns to in clinical practice and their accompanying data, Mauro also dissected the November 2025 FDA approval of generic dasatinib (Phyrago) tablets for patients with CML and acute lymphoblastic leukemia. More specifically, Mauro outlined what this approval means for patients who need concomitant gastric acid–reducing agents like proton pump inhibitors.